Immuno-oncology technology最新文献

{"title":"ESMO","authors":"","doi":"10.1016/S2590-0188(25)00506-4","DOIUrl":"10.1016/S2590-0188(25)00506-4","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"28 ","pages":"Article 101546"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145839349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intratumoral microbiome is associated with the response to cancer immunotherapy in lung cancer patients with high PD-L1 expression","authors":"F. Shoji ,&nbsp;T. Kawabata ,&nbsp;K. Kosai ,&nbsp;T. Fujishita ,&nbsp;R. Toyozawa ,&nbsp;S. Shimamatsu ,&nbsp;K. Ito ,&nbsp;K. Taguchi ,&nbsp;M. Yamaguchi","doi":"10.1016/j.iotech.2025.101066","DOIUrl":"10.1016/j.iotech.2025.101066","url":null,"abstract":"<div><h3>Background</h3><div>High expression of tumoral programmed death-ligand 1 (PD-L1) [high PD-L1 tumor proportion score (TPS)] is a predictive biomarker of response to cancer immunotherapy in lung cancer; however, its predictiveness is insufficient. Recently, resident microbiomes in several organs including the lung have been demonstrated to control host immunity but their role in the response to cancer immunotherapy is still unknown.</div></div><div><h3>Materials and methods</h3><div>This single-center, retrospective study analyzed 32 high PD-L1-TPS lung cancer patients treated with immune checkpoint inhibitors (ICI). We carried out shotgun metagenome sequencing using frozen tumor tissues, then analyzed the correlation between the intratumoral microbiota and response to ICI therapy.</div></div><div><h3>Results</h3><div>In this study, only 56.3% of patients with high PD-L1-TPS showed response to ICI therapy. Among 11 significant compositional differences in intratumoral microbiota observed in ICI responders, there was significantly longer progression-free survival (PFS) in patients with abundant <em>Tetrasphaera</em> and <em>Mesorhizobium</em>. Of patients with these abundant microbiota, 83.3% showed response to ICI therapy and all patients without these microbiota were ICI nonresponders (<em>P</em> = 0.0050). There were significant differences among three groups classified by the abundance of <em>g_Tetrasphaera</em> and <em>g_Mesorhizobium</em> (PFS, <em>P</em> = 0.0016 and overall survival, <em>P</em> = 0.0013). Twenty pathway modules were enriched in ICI responders and eight were enriched in ICI nonresponders.</div></div><div><h3>Conclusions</h3><div>This study revealed the specific compositions of intratumoral microbiota as demonstrating relevance to response to ICI therapy in high PD-L1-TPS lung cancer patients. The intratumoral microbiota components <em>Tetrasphaera</em> and <em>Mesorhizobium</em> may have a key role in determining the response to cancer immunotherapy for lung cancer.</div></div>","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"28 ","pages":"Article 101066"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145467025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sites of metastases before systemic treatment influence progression patterns and survival in stage IV melanoma patients","authors":"I.A. Vergara ,&nbsp;S.N. Lo ,&nbsp;I. Li ,&nbsp;J.W. Conway ,&nbsp;X. Fu ,&nbsp;A.M. Menzies ,&nbsp;M.S. Carlino ,&nbsp;R.A. Scolyer ,&nbsp;G.V. Long ,&nbsp;I.P. da Silva","doi":"10.1016/j.iotech.2025.101078","DOIUrl":"10.1016/j.iotech.2025.101078","url":null,"abstract":"<div><h3>Background</h3><div>Metastatic sites influence response rates to immune checkpoint inhibitors (ICI) and survival, suggesting anatomical locations impact treatment outcomes. This study examines how baseline metastatic sites affect progression patterns and survival in melanoma patients receiving first-line ICI or BRAF/MEK inhibitors (BRAF/MEKi).</div></div><div><h3>Methods</h3><div>Metastatic site presence and lesion counts at baseline and progression were captured chronologically for 347 ICI-treated and 210 BRAF/MEKi-treated patients using a novel graph representation. This novel approach enabled systematic comparison of progression patterns post-therapy failure across patients by providing a standardized representation of patterns of progression in patients with distinct clinical histories. Associations of baseline metastatic sites with progression patterns and progression-free survival (PFS) were assessed.</div></div><div><h3>Results</h3><div>Patients with baseline brain metastasis had higher progression rates in the brain (67% for ICI, 61% for BRAF/MEKi) than those without (21% for ICI, 32% for BRAF/MEKi). Among ICI-resistant patients (<em>n</em> = 91), brain progression occurred in 79.4% with baseline brain metastasis (<em>n</em> = 34) versus 19.3% without (<em>n</em> = 57). For both treatment modalities, faster progression in the brain occurred when present at baseline. First-line ICI patients with brain metastasis at baseline had worse PFS than patients without brain metastasis at baseline (hazard ratio 1.9, 95% confidence interval 1.31-2.78, <em>P</em> &lt; 0.01) with patients with more than three brain lesions at baseline having worst 1-year PFS (28%) compared with patients with one to three brain lesions (49%) and with patients with no brain lesions at baseline (62%).</div></div><div><h3>Conclusions</h3><div>Baseline metastatic sites, treatment modality, and resistance type modulate progression patterns and survival in melanoma patients treated with first-line ICI or BRAF/MEKi.</div></div>","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"28 ","pages":"Article 101078"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145466957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"74TiP Unlock tarlatamab: A phase II, multicenter, open-label, study investigating tarlatamab in patients with metastatic/locally advanced small cell lung cancer and other poorly differentiated neuroendocrine carcinomas with integrated biomarker analyses","authors":"M.F. Mosele ,&nbsp;M. Texier ,&nbsp;M. Roulleaux Dugage ,&nbsp;M. Kamal ,&nbsp;A. Peltier ,&nbsp;J.E. Rodriguez ,&nbsp;C. Nicotra ,&nbsp;M. Ngo Camus ,&nbsp;L. Tselikas ,&nbsp;C. Serhal ,&nbsp;L. Bigot ,&nbsp;M.R. Ghigna ,&nbsp;M.A. Bani ,&nbsp;P. East ,&nbsp;M. Pogorzelski ,&nbsp;M. Oser ,&nbsp;L. Friboulet ,&nbsp;C.P. Massard ,&nbsp;F. André ,&nbsp;Y. Loriot","doi":"10.1016/j.iotech.2025.101560","DOIUrl":"10.1016/j.iotech.2025.101560","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"28 ","pages":"Article 101560"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145839443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"98P Interleukin-6 levels and its association with interleukin-2 induced toxicities in patients receiving adoptive cell transfer with tumor-infiltrating lymphocytes: A retrospective cohort study","authors":"A.M. Schmitt ,&nbsp;D. König ,&nbsp;B. Kasenda ,&nbsp;H. Thut ,&nbsp;A. Zingg ,&nbsp;R. Ritschard ,&nbsp;B. Riebesehl ,&nbsp;A. Chirindel ,&nbsp;K. Glatz ,&nbsp;E. Kappos ,&nbsp;J. Van den Berg ,&nbsp;A. Holbro ,&nbsp;N. Khanna ,&nbsp;L.T. Jeker ,&nbsp;J. Halter ,&nbsp;J. Passweg ,&nbsp;M. Binder ,&nbsp;A. Zippelius ,&nbsp;H. Läubli","doi":"10.1016/j.iotech.2025.101183","DOIUrl":"10.1016/j.iotech.2025.101183","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"28 ","pages":"Article 101183"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145839489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"27P Dissecting the dynamics of the cytokine profile in breast cancer patients: From mediators of chronic inflammation to potential biomarkers","authors":"S. Manzano ,&nbsp;U. Álvarez ,&nbsp;A. de la Maza ,&nbsp;I. Garmendia ,&nbsp;J. Miner ,&nbsp;A. Lahuerta ,&nbsp;M. Otano ,&nbsp;A. Paisan Ruiz ,&nbsp;I. Alvarez Lopez ,&nbsp;S. Lopez-Tarruella Cobo ,&nbsp;L. de la Cruz Merino ,&nbsp;A. Urruticoechea ,&nbsp;M. Caffarel","doi":"10.1016/j.iotech.2025.101110","DOIUrl":"10.1016/j.iotech.2025.101110","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"28 ","pages":"Article 101110"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145839628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"82P Locoregional administration of autologous tumor infiltrating lymphocytes in patients with uveal melanoma and liver metastases (HAITILS trial)","authors":"A.F. Nelson ,&nbsp;R. Riise ,&nbsp;S. Alsen ,&nbsp;W-K.A. Wong ,&nbsp;P. Carlson ,&nbsp;S. Edman ,&nbsp;J. Holgersson ,&nbsp;R. Olofsson Bagge ,&nbsp;I. Johansson ,&nbsp;M. Sadik ,&nbsp;L. Edenbrandt ,&nbsp;L. Nilsson ,&nbsp;J.A. Nilsson ,&nbsp;L. Ny","doi":"10.1016/j.iotech.2025.101167","DOIUrl":"10.1016/j.iotech.2025.101167","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"28 ","pages":"Article 101167"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145839705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"47P Whole-exome sequencing (WES) of ctDNA for biomarker identification in advanced non-small cell lung cancer (NSCLC)","authors":"A. Lopez Gutierrez ,&nbsp;L. Posado-Domínguez ,&nbsp;J.L. Garcia Hernandez ,&nbsp;P. Gonzalez Santa Catalina ,&nbsp;E. del Barco Morillo ,&nbsp;J.C. Redondo González ,&nbsp;N. Egido Iglesias ,&nbsp;A. Canal Alonso ,&nbsp;L. Corvo Félix ,&nbsp;E. Pablo Martín ,&nbsp;C.J. Fajardo Flores ,&nbsp;A. Rodrigues ,&nbsp;L. Bellido Hernández ,&nbsp;E. Fonseca Sánchez ,&nbsp;J.J. Cruz Hernandez ,&nbsp;J.M. Corchado ,&nbsp;A. Olivares Hernandez","doi":"10.1016/j.iotech.2025.101130","DOIUrl":"10.1016/j.iotech.2025.101130","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"28 ","pages":"Article 101130"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145839768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"104P Leveraging endogenous TIL responses to develop noncanonical peptide-directed TCR therapies","authors":"T.M. Hulen,&nbsp;M.D.D. Crowther,&nbsp;L. Schuster,&nbsp;S. Khan,&nbsp;A. Schina,&nbsp;M. Donia,&nbsp;M.H. Andersen,&nbsp;I.M. Svane,&nbsp;Ö. Met","doi":"10.1016/j.iotech.2025.101189","DOIUrl":"10.1016/j.iotech.2025.101189","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"28 ","pages":"Article 101189"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145836357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"77MO A phase I trial of IMA203CD8, a PRAME-directed TCR T cell therapy in PRAME-positive solid tumors","authors":"A. Busse ,&nbsp;D.M. Araujo ,&nbsp;L.F. Hernandez-Aya ,&nbsp;A.M. Tsimberidou ,&nbsp;K. Wetzko ,&nbsp;D. Davar ,&nbsp;T.A.W. Holderried ,&nbsp;D. Jäger ,&nbsp;A.J. Olszanski ,&nbsp;S.P. Patel ,&nbsp;E.M. Wagner-Drouet ,&nbsp;T.P. Wang ,&nbsp;A. Maia ,&nbsp;S. Hengler ,&nbsp;D. Krishna ,&nbsp;A. Mayer-Mokler ,&nbsp;D. Pankov ,&nbsp;C.M. Britten ,&nbsp;W. Alsdorf ,&nbsp;M. Wermke","doi":"10.1016/j.iotech.2025.101162","DOIUrl":"10.1016/j.iotech.2025.101162","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"28 ","pages":"Article 101162"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145836571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}